Literature DB >> 12135034

Overnight efficacy of polyethylene glycol laxative.

Jack A Di Palma1, Julie R Smith, Mark vB Cleveland.   

Abstract

OBJECTIVES: Clinical studies in constipated adult patients have shown that a 17- or 34-g daily dose of polyethylene glycol (PEG) 3350 (MiraLax) is safe and effective for the treatment of constipation, with the best efficacy seen in wk 2 of treatment. The purpose of this study was to determine an optimal dose of PEG to provide satisfactory relief of constipation within 24 h.
METHODS: A total of 24 adult study subjects who met Rome II criteria for constipation were randomized in a double-blind, parallel pilot study to receive a single dose of placebo or PEG laxative at doses of 51, 68, or 85 g in 500 ml of flavored water. Over a 72-h period, subjects rated bowel movements (BM), completeness of evacuation, and satisfaction.
RESULTS: The 68-g dose seemed to be most satisfactory. Five of six subjects had a BM within 24 h. The time to first BM was 14.8 h for 68 g versus 27.3 h for placebo (p = NS). The time to second BM was 19.2 h versus 47.2 h for 68 g and placebo, respectively (p = 0.003). Of the subjects receiving 68 g of PEG, 50% and 100% reported complete evacuation for the first and second BM, respectively. The average number of BMs in 24 h for placebo, 51 g, 68 g, and 84 g were 0.5, 2.2, 2.2, and 4.2, respectively (p = 0.004). There were no adverse reactions, and no patient reported incontinence or complained of cramps or diarrhea at any dose. There were no changes in measured electrolytes, calcium, glucose, BUN, creatinine, or serum osmolality.
CONCLUSIONS: A 68-g dose of PEG laxative seems to provide safe and effective relief in constipated adults within a 24-h period.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135034     DOI: 10.1111/j.1572-0241.2002.05840.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  15 in total

Review 1.  Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment.

Authors:  P Paré; Ronald Bridges; Malcolm C Champion; Subhas C Ganguli; James R Gray; E Jan Irvine; Victor Plourde; Pierre Poitras; Geoffrey K Turnbull; Paul Moayyedi; Nigel Flook; Stephen M Collins
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

2.  Fecal impaction.

Authors:  Farshid Araghizadeh
Journal:  Clin Colon Rectal Surg       Date:  2005-05

Review 3.  American Gastroenterological Association technical review on constipation.

Authors:  Adil E Bharucha; John H Pemberton; G Richard Locke
Journal:  Gastroenterology       Date:  2013-01       Impact factor: 22.682

4.  Use of Powder PEG-3350 as a Sole Bowel Preparation: Clinical Case Series of 245 Patients.

Authors:  Manish Arora; Patrick I Okolo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-07

Review 5.  Chronic Constipation.

Authors:  Adil E Bharucha; Arnold Wald
Journal:  Mayo Clin Proc       Date:  2019-05-01       Impact factor: 7.616

6.  Medical treatment of constipation.

Authors:  Jonathan D Siegel; Jack A Di Palma
Journal:  Clin Colon Rectal Surg       Date:  2005-05

Review 7.  Review of the treatment options for chronic constipation.

Authors:  John F Johanson
Journal:  MedGenMed       Date:  2007-05-02

8.  Medical management of constipation.

Authors:  Meredith Portalatin; Nathaniel Winstead
Journal:  Clin Colon Rectal Surg       Date:  2012-03

9.  Fecal impaction: a cause for concern?

Authors:  Izi Obokhare
Journal:  Clin Colon Rectal Surg       Date:  2012-03

Review 10.  Chronic Constipation: a Review of Current Literature.

Authors:  Hani Sbahi; Brooks D Cash
Journal:  Curr Gastroenterol Rep       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.